



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/42, C12N 1/20, C12P 21/08, C07H 21/04, C07K 1/00, 16/00, G01N 33/53, 33/542	A1	(11) International Publication Number: WO 97/34636 (43) International Publication Date: 25 September 1997 (25.09.97)
--	----	--

(21) International Application Number: PCT/US97/04696 (22) International Filing Date: 19 March 1997 (19.03.97) (30) Priority Data: 60/013,708 20 March 1996 (20.03.96) US (60) Parent Application or Grant (63) Related by Continuation US 60/013,708 (CON) Filed on 20 March 1996 (20.03.96) (71) Applicant (for all designated States except US): IM- MUNOMEDICS, INC. [US/US]; 300 American Road, Morris Plains, NJ 07950 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): LEUNG, Shui-on [GB/US]; 254 Kings Road, Madison, NJ 07940 (US). LOSMAN, Michele, J. [FR/US]; 475 Berkeley Avenue, South Orange, NJ 07079 (US). HANSEN, Hans [US/US]; 2617 North Burgee Drive, Mystic Island, NJ 08087 (US).	(74) Agents: SAXE, Bernhard, D. et al.; Foley & Lardner, Suite 500, 3000 K Street, N.W., Washington, DC 20007-5109 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
---	---

Published

*With international search report.
Before the expiration of the time limit for amending the
claims and to be republished in the event of the receipt of
amendments.*

(54) Title: HUMANIZATION OF AN ANTI-CARCINOEMBRYONIC ANTIGEN ANTI-IDIOTYPE ANTIBODY AND USE AS A TUMOR VACCINE AND FOR TARGETING APPLICATIONS

(57) Abstract

A humanized form of an anti-idiotypic antibody to CEA, e.g., hWI2, has conserved immunoreactivity. The clinical benefits of anti-CEA antibodies are maximized by using the humanized anti-idiotypic as a clearing agent for anti-CEA antibodies or antibody fragments. The humanized anti-idiotypic also can be used as an immunogenic vaccine.